Zhengbo M. Song

Targeting JOSD2 degrades β-catenin to suppress colorectal cancer metastasis by disrupting RAS/ERK/β-catenin axis.

Journal: Acta pharmacologica Sinica

Published: December 05, 2025

Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.

Journal: The Lancet. Respiratory medicine

Published: October 19, 2025

The impact of comprehensive local therapy on treatment outcomes of non-small cell lung cancer with solitary skeletal oligometastasis.

Journal: Journal of bone oncology

Published: February 15, 2025

Correction: The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 05, 2024

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study.

Journal: Investigational new drugs

Published: November 18, 2024

Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database.

Journal: International journal of clinical pharmacy

Published: September 21, 2024

Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 21, 2024

The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 07, 2024

Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 09, 2024

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 09, 2024

Targeting JOSD2 degrades β-catenin to suppress colorectal cancer metastasis by disrupting RAS/ERK/β-catenin axis.

Targeting JOSD2 degrades β-catenin to suppress colorectal cancer metastasis by disrupting RAS/ERK/β-catenin axis.

Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.

Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.

The impact of comprehensive local therapy on treatment outcomes of non-small cell lung cancer with solitary skeletal oligometastasis.

The impact of comprehensive local therapy on treatment outcomes of non-small cell lung cancer with solitary skeletal oligometastasis.

Correction: The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors.

Correction: The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors.

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study.

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study.

Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database.

Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database.

Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma.

Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma.

The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors.

The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors.

Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment.

Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment.

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.

Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma.

Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma.

Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations.

Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations.